Five-year subgroup analysis of tafasitamab plus lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma

被引：0
|
作者：
Duell, Johannes
Abrisqueta, Pau
Dreyling, Martin H.
Gaidano, Gianluca
Barca, Eva Gonzalez
Jurczak, Wojciech
Maddocks, Kami J.
Menne, Tobias
Tournilhac, Olivier
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles A.
Nagy, Zsolt
机构：
[1] Univ Klin Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] Vall Hebron Univ Hosp, Dept Hematol, Vall Hebron Inst Oncol VHIO, Barcelona, Spain
[3] Ludwig Maximilians Univ Hosp, Munich, Germany
[4] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy
[5] Univ Barcelona, Inst Catal Oncol, Hosp Duran Reynals, IDIBELL, Barcelona, Spain
[6] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Clin Oncol, Krakow, Poland
[7] Ohio State Univ Wexner Med Ctr, Dept Internal Med, Arthur G James Comprehens Canc Ctr, Columbus, OH USA
[8] Newcastle Tyne Hosp, Freeman Hosp, Newcastle Upon Tyne, Tyne & Wear, England
[9] CHU Clermont Ferrand, Clermont Ferrand, France
[10] MorphoSys AG, Planegg, Germany
[11] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[12] Semmelweis Univ, Budapest, Hungary
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19522
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Kambhampati, Swetha
    Kallam, Avyakta
    Borogovac, Azra
    Chen, Lu
    Puverel, Sandrine
    Johnson, Jennifer
    Melgar, Ivana
    Baird, John H.
    Danilov, Alexey
    Godfrey, James
    Khan, Niloufer
    Mei, Matthew
    Phillips, Tycel J. J.
    Siddiqi, Tanya
    Shouse, Geoffrey
    Zain, Jasmine
    Kwak, Larry W.
    Rosen, Steven T.
    Forman, Stephen J.
    Song, Joo Y.
    Herrera, Alex F.
    Budde, Elizabeth
    BLOOD, 2024, 144 : 17421 - 17422
  • [42] Real-World Experience Using Tafasitamab Plus Lenalidomide and/or Loncastuximab Tesirine in a Predominately Hispanic Population with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Latiolais, Heidi
    Horowitz, Justin
    Michalek, Joel
    Duque, Adolfo Enrique Diaz
    BLOOD, 2024, 144 : 7780 - 7781
  • [43] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO
    Martin Garcia-Sancho, A.
    Baile, M.
    Rodriguez, G.
    Dlouhy, I.
    Sancho, J. M.
    Jarque, I.
    Gonzalez-Barca, E.
    Salar, A.
    Espeso, M.
    Grande, C.
    Bergua, J.
    Montes-Moreno, S.
    Redondo, A.
    Enjuanes, A.
    Campo, E.
    Lopez-Guillermo, A.
    Caballero, D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (02) : 202 - 211
  • [44] Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello, Patrizia
    Steiner, Normann
    Willenbacher, Wolfgang
    Ferrero, Simone
    Ghione, Paola
    Marabese, Alessandra
    Pitini, Vincenzo
    Cuzzocrea, Salvatore
    Mian, Michael
    ONCOLOGIST, 2016, 21 (09): : 1107 - 1112
  • [45] Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
    Zinzani, Pier Luigi
    Pellegrini, Cinzia
    Gandolfi, Letizia
    Stefoni, Vittorio
    Quirini, Federica
    Derenzini, Enrico
    Broccoli, Alessandro
    Argnani, Lisa
    Pileri, Stefano
    Baccarani, Michele
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (06): : 462 - 466
  • [46] Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial
    Wang, Yucai
    Wagner-Bartak, Nicolaus
    Zhou, Shouhao
    Fowler, Nathan
    Dela Rosa, Maria Lourdes
    Zhao, Donglu
    Romaguera, Jorge E.
    Neelapu, Sattva S.
    Hagemeister, Fredrick B.
    Fanale, Michelle A.
    Oki, Yasuhiro
    Shah, Jatin J.
    Thomoas, Sheeba K.
    Hosing, Chitra M.
    Zhang, Liang
    Badillo, Maria
    Chen, Wendy
    Cai, Qingqing
    Zou, Dehui
    Champlin, Richard E.
    Fayad, Luis E.
    Lee, Hun Ju
    Wang, Michael
    BLOOD, 2015, 126 (23)
  • [47] EL-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years
    Duell, Johannes
    Jurczak, Wojciech
    Liberati, Anna Marina
    Halka, Janusz
    Carbo, Esther Pena
    Abrisqueta, Pau
    Maddocks, Kami J.
    Dreyling, Martin
    Rosenwald, Andreas
    Bakuli, Abhishek
    Amin, Aasim
    Gurbanov, Konstantin
    Salles, Gilles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S375 - S375
  • [48] Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
    Abdulhaq, Haifaa
    Hwang, Andrew
    Mahmood, Omar
    ONCOTARGETS AND THERAPY, 2023, 16 : 617 - 629
  • [49] A MULTICENTER PHASE II STUDY OF BENDAMUSTINE WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Kim, W. S.
    Ando, K.
    Niitsu, N.
    Ogura, M.
    Takahashi, N.
    Uike, N.
    Eom, H. Seok
    Chae, Y. S.
    Tobinai, K.
    Terauchi, T.
    Tateishi, U.
    Tatsumi, M.
    Suh, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
  • [50] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Kayoko Murayama
    Toru Kiguchi
    Koji Izutsu
    Yoshihiro Kameoka
    Michihiro Hidaka
    Harumi Kato
    Shinya Rai
    Junya Kuroda
    Kenichi Ishizawa
    Satoshi Ichikawa
    Kiyoshi Ando
    Michinori Ogura
    Koji Fukushima
    Yasuhito Terui
    Annals of Hematology, 2022, 101 : 979 - 989
12345